NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
25 hedge funds and large institutions have $65.3M invested in NKGen Biotech, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 33 closing their positions.
55% less funds holding
Funds holding: 55 → 25 (-30)
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
61% less capital invested
Capital invested by funds: $168M → $65.3M (-$103M)
91% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTCM
Fir Tree Capital Management
New York
|
+$2.58M |
| 2 |
SFM
Spartan Fund Management
Toronto, Ontario,
Canada
|
+$2.46M |
| 3 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$1.08M |
| 4 |
Walleye Capital
New York
|
+$205K |
| 5 |
VF
Virtu Financial
New York
|
+$126K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$13.7M |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$8.86M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$8.17M |
| 4 |
CIM
Cowen Investment Management
New York
|
-$7.6M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$5.12M |
NKGN Hedge Fund Activity: Q2 2023 in Review
25 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q2 2023, worth a combined $65.3M — down 61% from $168M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of NKGN and 3 opened new positions — a net loss of 30 holders — while 11 trimmed existing stakes and 5 added.
The largest buyer was Fir Tree Capital Management, adding an estimated $2.58M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $13.7M sold.
- 25 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q2 2023, down from 55 in Q1 2023.
- Funds reported $65.3M of NKGen Biotech, Inc. Common Stock stock for Q2 2023, down 61% quarter-over-quarter.
- 3 funds opened new NKGen Biotech, Inc. Common Stock positions in Q2 2023 and 33 closed out, a net change of -30 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q2 2023 was Fir Tree Capital Management, an estimated $2.58M added.
- The largest NKGen Biotech, Inc. Common Stock seller in Q2 2023 was Adage Capital Partners, an estimated $13.7M sold.
Based on aggregated 13F filings for Q2 2023.